Good afternoon,
Max Health is pleased to announce the following news regarding its partner Orion.
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.
Company website: https://www.orion.fi/en/
Since 2020 Orion has expanded its commercial footprint to the Asia Pacific region (Malaysia, Singapore and Thailand). This year the company is establishing its own operations in New Zealand and Australia.
Max Health™ was established in 2008 and distributes a variety of pharmaceutical and medical products in New Zealand for a number of international partners. Their expertise, local knowledge and network of contacts has helped build a solid reputation for reliability and innovation in the NZ pharmaceutical sector. They have distributed a number of Orion products in NZ since their first Orion launch in 2012.
Orion has plans to invest in NZ and to offer an expanded range of products to NZ patients. While Orion has committed to establishing a NZ subsidiary, it is important to note that they have retained the services of Max Health to its represent its products to NZ customers, and to bring its products under one umbrella in this country. Max Health is delighted to be partnering with Orion in this exciting expansion of their product portfolio in NZ.
If you have any questions please feel free to contact me.
Best regards,
Patrick Forrester
Director- Max Health Ltd
Mob: 021 311 357 Ph: +64 9 815 2664
